Sixty isolates of Enterobacteriaceae resistant to ␤-lactam antibiotics were collected over a period of 2 years in Switzerland and screened by hybridization for the carriage of SHV genes. Thirty-four positive strains were found, and their SHV genes were amplified and sequenced. SHV extended-spectrum ␤-lactamases (ESBLs) were found: 13 strains contained SHV-2a, 12 harbored SHV-2, and SHV-5 was found twice. Four strains were shown to contain SHV-1. In addition, we report two new SHV variants, termed SHV-11 (non-ESBL) and SHV-12 (ESBL). In spite of the carriage of SHV ESBLs, many strains showed only low resistance to one or more third-generation cephalosporins. In addition, 26 did not transfer the bla SHV gene in mating experiments.
RESULTS

Detection of SHV ESBL-producing clinical isolates.
Of 60 strains with reduced susceptibility to expanded-spectrum cephalosporins which had been collected, 34 (24 Klebsiella pneumoniae, 7 Escherichia coli, 1 Enterobacter cloacae, and 2 Salmonella enterica serotype wien) hybridized with the intragenic bla SHV probe (data not shown). The bla SHV genes were amplified by PCR, and the presence of bla SHV-ESBL was established in 29 strains by restriction enzyme digests of the resulting 1,018-bp amplimers as described elsewhere (42) . These results were confirmed by the nucleotide sequencing of all 34 amplimers (Table  1) . Five strains contained SHV non-ESBL enzymes.
Nucleotide sequences. The sequencing of the 34 amplimers revealed that 13 strains contained SHV-2a, 12 strains contained SHV-2, 2 isolates harbored SHV-5, and 4 strains carried SHV-1, a non-extended-spectrum SHV. In addition, two new SHV variants, termed SHV-11 and SHV-12, were detected in one and two isolates, respectively (see Table 2 ). These variants differ from SHV-1 and SHV-5, respectively, by a leucine-toglutamine substitution at position 35 of the SHV protein (numbering in accordance with Ambler et al. [1] ), analogous to SHV-2a (46) . The amino acid changes of SHV-11 and SHV-12 are listed in Table 3 . The nucleotide sequences of the SHV genes of all four strains carrying SHV-1 as well as that of the SHV-11 gene showed the same differences from the only other registered DNA sequence of SHV-1 (35) , as do all other bla SHV sequences so far reported. The dissimilarities in the sequences reported by Mercier and Levesque (35) concern the amino acid exchanges lysine to asparagine at position 192 (lysine 1923asparagine) and leucine 1933valine, followed by an additional glycine.
Furthermore, the interchange of alanine 140 and threonine 141 in the amino acid sequence of SHV-1 reported by Barthélémy et al. (6) was not observed in any of our SHV-1 genes. Several of the sequenced SHV genes contained additional silent point mutations within the open reading frames, compared to known sequences. Some of them are reported here for the first time. They are listed in Table 2 .
The most frequent silent point mutation was found in the coding triplet for leucine 138, which is, in the majority of the bla SHV-2 genes (10 of 12), encoded by CTA, whereas in 12 of 13 bla SHV-2a genes it is encoded by CTG.
Molecular epidemiology. Ribotyping showed that 13 strains could be assigned to five different groups (designated ribotypes A to E). Ribotypes A, B, C, and E comprised two isolates each, whereas ribotype D included five strains (see Table 2 ). All other strains were found to have unique ribotyping patterns. K. were isolated over a period of 2 weeks initially from the blood and subsequently from the cerebrospinal fluid of a patient suffering from a skull injury. Three of these strains were shown to carry SHV-1, one strain harbored SHV-2, and one harbored SHV-2a (Table 2 ). Conjugative transfer of resistance determinants from clinical isolates to E. coli was successful in 11 of 34 cases. Large plasmids, which were estimated to be approximately 80 kb (data not shown), were isolated from all transconjugants except EK-1 and KZ-6, which contained smaller plasmids of approximately 30 and 5 kb, respectively. Plasmid isolation was unsuccessful from KZ-7 and KZ-10. The plasmids and the total DNA of KZ-6, KZ-7, and KZ-10 were subjected to restriction endonuclease digestions with BamHI. However, no prevailing plasmid fingerprint was detected, with only KL-2, EL-4, and EN-1 sharing strong comigrating bands, together with KZ-6, in which weak plasmid bands became visible only after restriction endonuclease treatment of the total DNA. All four strains had a restriction fragment of 3.6 kb and one of 1 kb in common (Fig. 1) . Subsequent hybridization with a bla SHV -specific probe revealed that these strains shared the location of the bla SHV gene on the 3.6-kb fragment. Several strains harbored two or more bla SHV genes, as shown in Fig. 1 . As can be seen by the absence of hybridizing bands in Fig. 1 , the transfer of resistance markers into HK225, yielding the transconjugants EL-1, KZ-7, and KZ-10, did not involve the expected bla SHV genes.
Phenotypical properties. MICs were determined to obtain a resistance pattern for each individual wild-type and transconjugant strain. The results are summarized in Table 1 . The clinical isolates harboring extended-spectrum SHVs were resistant to most ␤-lactam antibiotics but retained susceptibility to imipenem. Several strains also exhibited resistance to the amoxicillin-clavulanic acid combination. The MICs of all thirdgeneration cephalosporins tested were somewhat low for several strains despite the carriage of extended-spectrum SHV genes by the strains. Others, for which the MICs of cefotaxime and ceftriaxone were high, remained susceptible to ceftazidime. This can be observed in strains KPLA-2, KPLA-7, KPZU-10, SWLA-1, and, most obviously, in ECLA-1, for which the MICs of cefotaxime and ceftriaxone are both Ն256 g/ml but that of ceftazidime is only 1 g/ml. These properties are shared by the respective transconjugants KL-2, KL-7, KZ-10, and EL-1 (Table 1) .
DISCUSSION
Sixty clinical isolates of Enterobacteriaceae that were considered to have either reduced susceptibility or resistance to ␤-lactam antibiotics in various clinical microbiology laboratories in Switzerland were subjected to further investigation. In general, the disk diffusion method is employed for susceptibility testing in these laboratories. However, it has been shown that such tests are not sufficiently sensitive for the detection of SHV ESBL-producing isolates (2, 12, 25, 42) . Bearing this in mind, one must assume that a number of ESBL producers pass through diagnostic microbiology laboratories undetected. This may account for the relatively low number of SHV-producing Enterobacteriaceae found during the two years of the survey. We identified strains carrying bla SHV-ESBL genes by the PCRNheI method described previously (42) and confirmed the results by nucleotide sequencing.
The results give an insight into the prevalence of various types of SHV derivatives in Switzerland, with SHV-2 and SHV-2a clearly prevailing. SHV-5 is frequent in Germany (7), Italy (33) , and England (16), and SHV-4 is frequent in France (15) . In addition, two new SHV variants, SHV-11 and SHV-12, are described here for the first time. They carry a leucine-toglutamine substitution at position 35. This point mutation, although far from the active site and known not to alter the isoelectric point of SHV-2a compared to that of SHV-2 (46), has been shown to have an influence on the resistance levels of the host strain (41) . Such variants, therefore, have to be considered independent SHV derivatives.
Interestingly, this particular point mutation is shared by the chromosomally encoded ␤-lactamase LEN-1 (3), which otherwise has nearly 90% amino acid identity with SHV-2. LEN-1 also has leucine 138 encoded by CTG, as do the majority of the SHV-2a genes sequenced in this survey. In contrast, leucine 138 in most SHV-2 enzymes presented here is encoded by CTA, as in the nucleotide sequence of SHV-1 reported by Mercier and Levesque (35) . These findings suggest a possible separate evolutionary development of SHV-2a and SHV-2. The fact that a number of silent mutations but no new amino acid exchanges were detected among the sequenced genes implies that the evolutionary range of variation of the SHV enzyme may be limited, possibly due to decreasing stability of the enzyme (50, 54) associated with reduced kinetic efficiency (12) .
Ribotyping gave no evidence for a clonal spread in any of the hospitals. The relationships between isolates could only be established in a few instances and did not involve more than five strains, as was the case with the K. pneumoniae isolates belonging to ribotype D. Moreover, the occurrence of various types of SHV derivatives even among the isolates of the same ribotype makes dissemination of resistance genes among the isolates improbable. This interpretation is supported by the fact that only 11 of the 34 clinical isolates transferred their resistance markers in mating experiments. Furthermore, 3 of the 11 transconjugants did not harbor an SHV gene, implying localization of that gene on a nonconjugative plasmid (see also reference 9) or on the chromosome within the respective donor. These three transconjugants, EL-1, KZ-7, and KZ-10, possibly contain other bla genes, probably on additional plasmids, which were transferred during conjugation rather than the bla SHV genes. This phenomenon of preferential transfer in the case of the carriage of multiple-resistance plasmids by a donor has been reported before (10, 31, 34, 51) and has been attributed to selective conditions during mating (10) . Some MICs for the three transconjugants (EL-1, KZ-7, and KZ-10) differ greatly from those for their donors, confirming that the bla SHV genes are not solely responsible for the entire resistance phenotypes of the respective donors. Moreover, other MICs shown in Table 1 indicate that some of the clinical isolates possess more than one ␤-lactamase because, although they carry the same SHV type enzyme, they show differences in susceptibility (e.g., KPLA-8 and KPLA-9 for cefepime and ECAA-1 and ECLA-1 for ceftazidime).
So far, SHV ESBLs have been found predominantly in Klebsiella spp. and E. coli. Few authors detected them in various serotypes of S. enterica (8, 18, 22, 23) , and all reported the presence of SHV-2. Several different TEM ESBLs have been found in this genus (4, 5, 36, 49, 57) . In this paper, two isolates carrying SHV-2a of S. enterica serotype wien, originally from Libyan patients, are reported. A careful sequence comparison revealed that a known S. typhimurium isolate (17) also carried an SHV-2a which had, however, been correctly termed SHV-2 in 1990 since SHV-2a was not differentiated from SHV-2 until 1991 (46) . This finding, together with the fact that all SHVcarrying Salmonella isolates were found in countries around the Mediterranean Sea, leads to the speculation that of the isolates reported previously, more may actually harbor SHV-2a than SHV-2.
ESBLs of the TEM and particularly of the SHV type are very rarely found in other Enterobacteriaceae genera, such as Enterobacter, Serratia, and Citrobacter, etc., in which chromosomal AmpC cephalosporinases predominate (24, 32) . Nevertheless, Serratia marcescens isolated in Greece has been reported to produce an SHV-5-like enzyme (identified by isoelectric focusing) (19) (14) . In this context, it is important to note that ENLA-1 is the first strain of E. cloacae reported to carry SHV-2.
Identical enzymes harbored by different isolates are known to vary in the levels of resistance to different antimicrobial compounds that they convey to their hosts (32, 41) . Consequently, the MICs presented here vary considerably ( Table 1) . The ceftazidime MICs for several strains analyzed in this study were modest. However, these strains exhibited elevated resistance to other third-generation cephalosporins, and consequently many had failed to be detected as ESBL producers when screened with a commercial ceftazidime/clavulanic acid synergy test (42) . In addition, other strains that were shown to harbor a bla SHV-ESBL gene remained apparently susceptible not only to ceftazidime but to all cephalosporins tested except cephalothin. Such strains, although they show reduced susceptibility to newer cephalosporins, remain susceptible according to the breakpoints established by the NCCLS. Interpretive problems that result from these circumstances are inevitable and especially misleading in the case of ceftazidime, which is recommended for the detection of ESBL producers (21, 28) . Moreover, treatment failures due to undetected ESBL-producing pathogens have already been reported (27) . No clear connection can be made between ␤-lactamase production and the in vitro resistance level of the host strain. Other factors must therefore be taken into consideration, e.g., permeability changes or the influence of the specific host environment.
Obviously, the mere presence of a bla SHV-ESBL gene in a host strain does not guarantee clear-cut high resistance to all extended-spectrum ␤-lactams in vitro. Nevertheless, such organisms should be regarded as potentially resistant to all extended-spectrum cephalosporins, regardless of the actual susceptibilities detected, as proposed on the basis of clinical and animal model data (20, 32, 45) .
One must conclude that more clinical isolates than anticipated harbor bla SHV-ESBL genes. In many cases they appear not to be transmissible, and their respective enzymes are often produced at low levels. A clonal spread or dissemination of a single resistance plasmid, therefore, would occur only sporadically, under special conditions, thus leading to nosocomial outbreaks.
